S&P 500   4,962.34 (-0.97%)
DOW   37,949.95 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   165.14 (-1.14%)
MSFT   399.39 (-1.21%)
META   481.55 (-4.04%)
GOOGL   154.02 (-1.28%)
AMZN   174.44 (-2.67%)
TSLA   147.17 (-1.84%)
NVDA   771.94 (-8.83%)
AMD   146.41 (-5.59%)
NIO   3.81 (-4.75%)
BABA   69.00 (+0.17%)
T   16.45 (+0.73%)
F   12.10 (+0.33%)
MU   106.73 (-4.65%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.20 (-0.20%)
AMC   3.19 (+9.25%)
PFE   25.97 (+2.28%)
PYPL   61.99 (-0.18%)
XOM   119.75 (+1.04%)
S&P 500   4,962.34 (-0.97%)
DOW   37,949.95 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   165.14 (-1.14%)
MSFT   399.39 (-1.21%)
META   481.55 (-4.04%)
GOOGL   154.02 (-1.28%)
AMZN   174.44 (-2.67%)
TSLA   147.17 (-1.84%)
NVDA   771.94 (-8.83%)
AMD   146.41 (-5.59%)
NIO   3.81 (-4.75%)
BABA   69.00 (+0.17%)
T   16.45 (+0.73%)
F   12.10 (+0.33%)
MU   106.73 (-4.65%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.20 (-0.20%)
AMC   3.19 (+9.25%)
PFE   25.97 (+2.28%)
PYPL   61.99 (-0.18%)
XOM   119.75 (+1.04%)
S&P 500   4,962.34 (-0.97%)
DOW   37,949.95 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   165.14 (-1.14%)
MSFT   399.39 (-1.21%)
META   481.55 (-4.04%)
GOOGL   154.02 (-1.28%)
AMZN   174.44 (-2.67%)
TSLA   147.17 (-1.84%)
NVDA   771.94 (-8.83%)
AMD   146.41 (-5.59%)
NIO   3.81 (-4.75%)
BABA   69.00 (+0.17%)
T   16.45 (+0.73%)
F   12.10 (+0.33%)
MU   106.73 (-4.65%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.20 (-0.20%)
AMC   3.19 (+9.25%)
PFE   25.97 (+2.28%)
PYPL   61.99 (-0.18%)
XOM   119.75 (+1.04%)
S&P 500   4,962.34 (-0.97%)
DOW   37,949.95 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   165.14 (-1.14%)
MSFT   399.39 (-1.21%)
META   481.55 (-4.04%)
GOOGL   154.02 (-1.28%)
AMZN   174.44 (-2.67%)
TSLA   147.17 (-1.84%)
NVDA   771.94 (-8.83%)
AMD   146.41 (-5.59%)
NIO   3.81 (-4.75%)
BABA   69.00 (+0.17%)
T   16.45 (+0.73%)
F   12.10 (+0.33%)
MU   106.73 (-4.65%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.20 (-0.20%)
AMC   3.19 (+9.25%)
PFE   25.97 (+2.28%)
PYPL   61.99 (-0.18%)
XOM   119.75 (+1.04%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BrainsWay Ltd. stock logo
BWAY
BrainsWay
$4.84
+1.0%
$5.87
$1.38
$7.61
$80.54M1.2123,052 shs33,301 shs
Spectral Medical Inc. stock logo
EDTXF
Spectral Medical
$0.32
$0.37
$0.17
$0.50
$89.64M0.8111,785 shs1,000 shs
PAVmed Inc. stock logo
PAVM
PAVmed
$1.85
-5.4%
$2.20
$1.60
$9.36
$16.92M0.8566,776 shs16,723 shs
TELA Bio, Inc. stock logo
TELA
TELA Bio
$4.72
-8.3%
$5.98
$4.23
$11.26
$116.35M0.95134,704 shs74,829 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-5.15%-9.62%-20.17%-24.80%+179.30%
Spectral Medical Inc. stock logo
EDTXF
Spectral Medical
0.00%+4.01%+8.17%-13.70%+42.16%
PAVmed Inc. stock logo
PAVM
PAVmed
-1.02%-2.50%-4.88%-28.31%-75.27%
TELA Bio, Inc. stock logo
TELA
TELA Bio
-0.39%+4.15%-3.74%-24.43%-44.20%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BrainsWay Ltd. stock logo
BWAY
BrainsWay
2.7823 of 5 stars
3.35.00.00.03.30.80.6
Spectral Medical Inc. stock logo
EDTXF
Spectral Medical
N/AN/AN/AN/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
1.6878 of 5 stars
3.00.00.04.33.10.80.0
TELA Bio, Inc. stock logo
TELA
TELA Bio
1.682 of 5 stars
3.52.00.00.01.81.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BrainsWay Ltd. stock logo
BWAY
BrainsWay
2.67
Moderate Buy$7.0044.63% Upside
Spectral Medical Inc. stock logo
EDTXF
Spectral Medical
N/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
2.00
Hold$21.001,038.21% Upside
TELA Bio, Inc. stock logo
TELA
TELA Bio
3.00
Buy$13.67189.55% Upside

Current Analyst Ratings

Latest PAVM, BWAY, EDTXF, and TELA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/22/2024
TELA Bio, Inc. stock logo
TELA
TELA Bio
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
3/22/2024
TELA Bio, Inc. stock logo
TELA
TELA Bio
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$15.00 ➝ $12.00
3/11/2024
BrainsWay Ltd. stock logo
BWAY
BrainsWay
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BrainsWay Ltd. stock logo
BWAY
BrainsWay
$31.78M2.53N/AN/A$2.50 per share1.94
Spectral Medical Inc. stock logo
EDTXF
Spectral Medical
$1.18M75.96N/AN/A($0.01) per share-32.17
PAVmed Inc. stock logo
PAVM
PAVmed
$2.45M6.91N/AN/A($3.35) per share-0.55
TELA Bio, Inc. stock logo
TELA
TELA Bio
$58.45M1.99N/AN/A$0.77 per share6.13

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-$4.20M-$0.13N/A60.50N/A-13.20%-10.05%-6.88%5/15/2024 (Estimated)
Spectral Medical Inc. stock logo
EDTXF
Spectral Medical
-$11.60M-$0.04N/AN/A-974.16%N/A-192.15%5/10/2024 (Estimated)
PAVmed Inc. stock logo
PAVM
PAVmed
-$64.18M-$9.33N/AN/A-2,617.25%N/A-85.99%5/21/2024 (Estimated)
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$46.66M-$2.07N/AN/AN/A-79.83%-201.62%-58.60%5/9/2024 (Estimated)

Latest PAVM, BWAY, EDTXF, and TELA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Spectral Medical Inc. stock logo
EDTXF
Spectral Medical
N/A-$0.02-$0.02-$0.02N/A$0.27 million
3/26/2024Q4 2023
PAVmed Inc. stock logo
PAVM
PAVmed
N/A-$1.57-$1.57-$1.16N/A$1.05 million
3/21/2024Q4 2023
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$0.44-$0.53-$0.09-$0.53$16.65 million$17.00 million
3/6/202412/31/2023
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-$0.03-$0.01+$0.02N/A$8.40 million$9.03 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BrainsWay Ltd. stock logo
BWAY
BrainsWay
N/AN/AN/AN/AN/A
Spectral Medical Inc. stock logo
EDTXF
Spectral Medical
N/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
N/AN/AN/AN/AN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BrainsWay Ltd. stock logo
BWAY
BrainsWay
N/A
5.68
5.30
Spectral Medical Inc. stock logo
EDTXF
Spectral Medical
N/A
2.18
2.09
PAVmed Inc. stock logo
PAVM
PAVmed
N/A
0.45
0.45
TELA Bio, Inc. stock logo
TELA
TELA Bio
2.15
4.23
3.45

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BrainsWay Ltd. stock logo
BWAY
BrainsWay
30.11%
Spectral Medical Inc. stock logo
EDTXF
Spectral Medical
N/A
PAVmed Inc. stock logo
PAVM
PAVmed
19.93%
TELA Bio, Inc. stock logo
TELA
TELA Bio
94.35%

Insider Ownership

CompanyInsider Ownership
BrainsWay Ltd. stock logo
BWAY
BrainsWay
19.00%
Spectral Medical Inc. stock logo
EDTXF
Spectral Medical
1.50%
PAVmed Inc. stock logo
PAVM
PAVmed
12.60%
TELA Bio, Inc. stock logo
TELA
TELA Bio
5.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BrainsWay Ltd. stock logo
BWAY
BrainsWay
13416.64 million13.48 millionNot Optionable
Spectral Medical Inc. stock logo
EDTXF
Spectral Medical
32278.64 million274.46 millionNot Optionable
PAVmed Inc. stock logo
PAVM
PAVmed
1079.17 million8.02 millionOptionable
TELA Bio, Inc. stock logo
TELA
TELA Bio
22724.65 million23.25 millionOptionable

PAVM, BWAY, EDTXF, and TELA Headlines

SourceHeadline
TELA Bio Launches Innovative Hernia Repair Device in the U.S. MarketTELA Bio Launches Innovative Hernia Repair Device in the U.S. Market
msn.com - April 17 at 9:16 AM
TELA Bio launches OviTex IHR for inguinal hernia repair in USTELA Bio launches OviTex IHR for inguinal hernia repair in US
msn.com - April 16 at 5:32 PM
TELA Bio announces US launch OviTex IHR for use in laparoscopic and robotic-assisted inguinal hernia repairTELA Bio announces US launch OviTex IHR for use in laparoscopic and robotic-assisted inguinal hernia repair
pharmabiz.com - April 16 at 7:29 AM
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia ProceduresTELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
globenewswire.com - April 15 at 7:00 AM
MDXG: Legal AvenuesMDXG: Legal Avenues
finance.yahoo.com - April 11 at 1:10 PM
TELA Bio Appoints Esteemed Surgeon Dr. Howard N. Langstein as Vice President of Medical AffairsTELA Bio Appoints Esteemed Surgeon Dr. Howard N. Langstein as Vice President of Medical Affairs
msn.com - April 10 at 6:58 AM
TELA Bio, Inc.: TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon StrategyTELA Bio, Inc.: TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
finanznachrichten.de - April 8 at 4:17 PM
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon StrategyTELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
globenewswire.com - April 8 at 7:00 AM
TELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024TELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024
msn.com - March 25 at 8:23 AM
Analysts Are Updating Their TELA Bio, Inc. (NASDAQ:TELA) Estimates After Its Full-Year ResultsAnalysts Are Updating Their TELA Bio, Inc. (NASDAQ:TELA) Estimates After Its Full-Year Results
finance.yahoo.com - March 24 at 5:22 PM
TELA Bio, Inc. (TELA) Q4 2023 Earnings Call TranscriptTELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 23 at 11:14 PM
TELA Bio Full Year 2023 Earnings: US$2.04 loss per share (vs US$2.72 loss in FY 2022)TELA Bio Full Year 2023 Earnings: US$2.04 loss per share (vs US$2.72 loss in FY 2022)
finance.yahoo.com - March 23 at 8:39 AM
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX(TM) - the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia SurgeryTELA Bio Announces U.S. Commercial Launch of LIQUIFIX(TM) - the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
stockhouse.com - March 22 at 5:36 PM
TELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call TranscriptTELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 22 at 5:36 PM
JMP Securities Reiterates Market Outperform Rating for TELA Bio (NASDAQ:TELA)JMP Securities Reiterates Market Outperform Rating for TELA Bio (NASDAQ:TELA)
marketbeat.com - March 22 at 2:10 PM
Piper Sandler Trims TELA Bio (NASDAQ:TELA) Target Price to $12.00Piper Sandler Trims TELA Bio (NASDAQ:TELA) Target Price to $12.00
marketbeat.com - March 22 at 10:25 AM
Q4 2023 TELA Bio Inc Earnings CallQ4 2023 TELA Bio Inc Earnings Call
finance.yahoo.com - March 22 at 7:36 AM
Recap: TELA Bio Q4 EarningsRecap: TELA Bio Q4 Earnings
benzinga.com - March 21 at 9:14 PM
TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023
msn.com - March 21 at 9:14 PM
TELA Bio Inc Reports Robust Revenue Growth in Q4 and Full Year 2023TELA Bio Inc Reports Robust Revenue Growth in Q4 and Full Year 2023
finance.yahoo.com - March 21 at 9:14 PM
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue EstimatesTELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
zacks.com - March 21 at 6:31 PM
Strategic Divestiture and Innovative Product Launch Fuel Buy Rating for TELA BioStrategic Divestiture and Innovative Product Launch Fuel Buy Rating for TELA Bio
markets.businessinsider.com - March 21 at 4:13 PM
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial ResultsTELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
finance.yahoo.com - March 21 at 4:13 PM
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial ResultsTELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
globenewswire.com - March 21 at 4:05 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BrainsWay logo

BrainsWay

NASDAQ:BWAY
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, the Asia Pacific, Europe, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Spectral Medical logo

Spectral Medical

OTCMKTS:EDTXF
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
PAVmed logo

PAVmed

NASDAQ:PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
TELA Bio logo

TELA Bio

NASDAQ:TELA
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.